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Traditionally, developments in the lab-
on-a-chip community have been techno-
logy-pushed, mainly guided by analytical
chemists, micro-machinists and material
scientists, rather than demand-pulled.
Applications such as LabChip1 from
Caliper (Fig. 1) and i-STAT from Abbott
Point of Care (Fig. 2) can now be found
on the market, solving practical pro-
blems for users. However, the field is still
lacking the promised breakthroughs and
this trend will continue as long as we
keep using a purely technologically-
driven approach. We therefore claim that
for the long-term survival of this field
a demand-pulled and market-driven
approach is of the utmost importance.
This article is framed around the medical
applications of lab-on-a-chip technolo-
gies in the Netherlands; however, the
results go beyond the Dutch context and
are relevant to other countries experienc-
ing similar technological changes.
Lab-on-a-chip scientists working on
medical applications must consider
diverse aspects such as user-friendliness,
industrial collaboration, social accep-
tance, health care insurance, and various
stakeholder interests in evaluating their
research. All these interrelated issues
make this already multifaceted area of
technological innovation even more com-
plex, but how should we deal with this?
Part of the answer might lie in the hands
of social scientists working in Innovation
Studies. Since the 1970s an approach
known as Technology Assessment (TA)
has been developed in an attempt to
deal with such complexities. In its ori-
gins, TA was merely an inward-looking
discipline aiming to predict the course of
technological advances and functioning
as a warning mechanism, thus striving to
forecast potential harmful effects. Due to
the unpredictable nature of innovations,
this linear approach (as in the famous
Chicago World Fair’s (1933) slogan:
‘‘science finds, industry applies, man
conforms’’) turned out not to be very
useful or reliable. Instead, an evolution-
ary model was proven to be more
suitable. This view is characterized by
feedback and feed-forward linkages
among all relevant stakeholders involved
in the different stages of development
and use of new technologies. In brief,
innovation is not a relay race in which
the baton is passed from the scientist, via
industry, to the end-user. It is much more
like a jigsaw puzzle, where the pieces
change while trying to fit them together.
Thus, TA became a process that not only
includes scientists and traditional stake-
holders in technology development, but
also gives a voice to previously under-
exposed stakeholders that bring other
relevant questions into the discussion.
Complexity increases when we realize
that the various stakeholders are subject
to change in their own environments,
such as public regulation leading to
health care competition. Also, cultural
differences in technology and markets
between geographical regions are impor-
tant issues to consider when applying the
technology globally. In other words, it is
more than technology alone that makes
or breaks innovative applications.
Another important issue to consider is
the so-called ‘Collingridge dilemma’
which states that technologies become
more difficult to influence over time
owing to investments and structures
already in place, while at its early stages
opportunities to steer are richest, but
hard to find.1 Adapted approaches of
TA, such as Constructive TA, attempt to
actively enrich technological develop-
ments while they are still on the drawing
board;{ involving all relevant stake-
holders’ wishes and needs.4,5 Thanks to
this wide variety of standpoints,
Constructive TA allows for a more
constructive assessment of opportunities
for promising technological applications
and it creates room to anticipate futures
under different scenarios.
Over the past year, a Constructive TA
project has been conducted for medical
applications of lab-on-a-chip technology
in the Netherlands. A wide diversity of
stakeholders were invited to debate the
future of the technology and identify
promising applications. The discussions
included economic, political and socio-
cultural aspects, and potentially success-
ful medical applications were also
debated. Before we continue to discuss
the possible added value of Constructive
TA we will give three examples that
illustrate cases where the technology
failed to develop as foreseen:
(1) In the early 1990s, authors such as
Manz et al., Harrison et al., and
Verpoorte et al., 2,3,6 had already touched
upon the promise of mTAS devices for
use outside the laboratory. For medical
devices this was soon linked up with the
ability to measure (bio)chemical sub-
stances when and wherever needed, a
process known as Point-of-Care testing.
However, very few of these applications
are on the market or in use today. This
gives rise to the question: What are the
chances of developing and facilitating the
application of these technologies such
that they can have an improving impact
on our everyday lives?
(2) General practitioners often see
patients with symptoms ranging from
fever to the early stages of a heart attack.
Fig. 1 LabChip1 from Caliper. Fig. 2 i-STAT from Abbott Point of Care.
{ Although we address early-stage tech-
nologies, the approach assumes that at least
a scientific community must be in place.
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Technically it is possible to equip general
practitioners with small instruments to
measure the level of specific proteins in
the patient’s blood and exclude the
possibility of a heart attack in the
diagnosis. Although these instruments
are already available on the market,
and everyone seems to recognize the
social and economic advantages of this
application, they are still not used by
Dutch general practitioners. Why is this?
(3) Frequent monitoring of the drug
levels in a patient’s blood will often
contribute significantly to the effective-
ness of treatments. Lab-on-a-chip tech-
nology offers possibilities to address
these needs with devices that can be used
either by general practitioners or by
patients themselves. However, these
needs are not being seriously addressed
by the health care industry. Why is this?
These anecdotes show that scientists
should not wait until they are
approached by the business community
looking for useful inventions to commer-
cialize. What is needed are meetings
between scientists, the medical com-
munity, industry, investors, health care
insurers, patient organisations and
government. This would reveal the rele-
vance of inventions in the early stages of
development, in other words: where
possibilities to steer are still viable.
The Dutch Constructive TA project on
lab-on-a-chip technology represents a
step forward in the assessment of valu-
able medical applications. It illustrates
how discussions in a trans-disciplinary
group, which includes all relevant stake-
holders, are highly valued by the partici-
pants. Most participants indicated that
the methodology helped them to articu-
late a broader range of aspects in their
interpretation of the future of these
applications. However, this is just the
initial step, and further efforts are
necessary to continue in this positive
direction.
What is the message for the lab-on-a-
chip community? Multi-stakeholder
initiatives, highlighting the relevance of
a wide variety of viewpoints in assessing
potential applications, are needed. This
implies initiatives that include ‘uncon-
ventional’ stakeholders such as health
care insurers, business investors, or gene-
ral practitioners. Furthermore, there is a
strong need for conducting experiments
that build on trans-disciplinary colla-
boration in the field of use. The authors
do not claim that every lab-on-a-chip
researcher should be involved in such
activities since basic research will always
be necessary. Nevertheless, for the dura-
tion of this field of endeavour, it is
important that part of the research also
focuses on closing the gap between
science and practice; after all ‘‘more than
technology alone’’ is required for success
in practical application.
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